JNJ price news: trading above key supports — RSI and MACD indicate overbought strength

Traders Union
All News
Financial News
Johnson & johnson slips 0.53% today

Highlights

Johnson & Johnson (JNJ) is trading at $191.87, down 0.53% daily but remains above its MA-20, MA-50, and MA-200, confirming a bullish setup.
JNJ declared a $1.30 quarterly dividend payable December 9, 2025, posted quarterly earnings of $2.26 per share on $24.02 billion revenue, and is exploring an intratumoral oncology collaboration.
Despite strong technical positioning and over 80% probability for near-term gains, daily and weekly RSI readings above 77.99 signal JNJ is overbought, with mixed momentum indicators forecasting potential short-term exhaustion.

Earnings support and oncology tie-up drive steady shareholder returns

Johnson & Johnson has declared a quarterly dividend of $1.30 per share to be paid on December 9, 2025, continuing its established dividend program. The company reported quarterly earnings of $2.26 per share on revenue of $24.02 billion, supporting ongoing shareholder returns. Johnson & Johnson is also exploring a potential collaboration in the field of intratumoral oncology, with leadership meetings planned for November 2025.

Conflicting momentum signals temper overbought rally above support

Technical analysis demonstrates JNJ trading decisively above its short-, medium-, and long-term moving averages, with prices supported by the Ichimoku kijun at $183.98 and the MA-50. Key technical signals are mixed: the daily MACD maintains a strong buy, whereas the ADX at 20.8 suggests weak trend strength. The RSI readings remain elevated at 77.99 daily and 86.01 weekly, both indicating overbought conditions, while Stoch RSI and CCI are also signaling potential exhaustion. BBP is neutral and the Awesome Oscillator does not confirm the ongoing uptrend, underscoring conflicting indicators. Today’s trading session opened only slightly lower and is marked by intraday weakness, hinting at short-term downward pressure despite the prevailing broader bullish trend.

Narrow range and high breakout odds as overbought risks build

Over the next five sessions, JNJ is expected to trade predominantly within a range of $192.81 to $193.08, with average prices near $192.94. The probability for near-term gains remains high, above 80%, driven by strong weekly RSI, MACD, and the upward placement above key moving averages. A consolidation scenario within this narrow band is the baseline outlook, while a decisive breakout above $193.08 could open the door to new highs. Any sustained fall below $191.94 could prompt a pullback toward dynamic support at the kijun around $183.98.

Viktoras Karapetjanc, expert at Traders Union, sees Johnson & Johnson’s ongoing dividend commitment and robust quarterly performance as strong signals of fundamental stability. Karapetjanc believes the positive technical trend, reinforced by bullish moving averages and healthy macro conditions, supports the stock’s high probability of maintaining or extending gains despite signs of short-term exhaustion. While mixed technical signals warrant some tactical caution, the analyst remains constructive given the company’s exploratory moves in oncology and persistent investor confidence. "As long as Johnson & Johnson holds above the $191.94 support, I expect buyers to stay in control with upside potential toward new highs if $193.08 is breached."

Previously, the company delivered strong quarterly results, with both earnings and revenue surpassing expectations. Last time, we reported that the statistical likelihood of further price gains was very low.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.